Zeven (dalbavancin) / RaQualia, AbbVie 
Welcome,         Profile    Billing    Logout  
 20 Diseases   6 Trials   6 Trials   1040 News 


«12345678910111213...1516»
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet? (Pubmed Central) -  May 14, 2023   
    Dalbavancin appears a cost-efficient option to reduce inpatient treatment costs by transitioning to an outpatient setting of patients with ABSSSI potentially exceeding the upper limit LOS. No abstract available
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Enrollment change, Trial withdrawal, Gram positive:  Dalbavancin Outpatient Pilot (clinicaltrials.gov) -  May 3, 2023   
    P4,  N=0, Withdrawn, 
    It seems to be a very promising therapy, with the potential to modify the natural history of no-options critical limb with diabetes complications, in terms of major amputation and overall survival rates. N=24 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  Molecular Epidemiology and Characterization of Multidrug-Resistant MRSA ST398 and ST239 in Himachal Pradesh, India. (Pubmed Central) -  May 1, 2023   
    All isolates were sensitive to linezolid, quinupristin-dulfopristin, dalbavancin, and cefazoline...The MRSA isolates produced staphylokinase and ?-hemolysis but were negative for bovine plasma coagulation tests. The predominant MRSA clones in Himachal Pradesh, India, were hospital-associated multi-drug resistant-MRSA ST239 with PVL and community-associated MRSA ST398.
  • ||||||||||  Nuvocid (oritavancin) / Melinta Therap, Cubicin (daptomycin) / Merck (MSD), Zeven (dalbavancin) / RaQualia, AbbVie
    Review, Journal:  Treatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge. (Pubmed Central) -  Apr 28, 2023   
    Some of them have scarce clinical experience and others are still under investigation and will be analyzed in this review. In addition, the need for prolonged treatment (6-8 weeks) to avoid relapses has forced to the consideration of other viable options as outpatient parenteral strategies, long-acting administrations with the new lipoglycopeptides (dalbavancin or oritavancin), and sequential oral treatments, which will also be discussed.
  • ||||||||||  teicoplanin / Generic mfg.
    Journal:  Cross-Talking of Pathway-Specific Regulators in Glycopeptide Antibiotics (Teicoplanin and A40926) Production. (Pubmed Central) -  Apr 28, 2023   
    Moreover, the heterologous expression of dbv3 in A. teichomyceticus led to a significant increase in teicoplanin production. Although the molecular background of these events merits further investigations, our results contribute to a deeper understanding of GPA biosynthesis regulation and offer novel biotechnological tools to improve their production.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal, Gram positive:  Dalbavancin in Gram-positive periprosthetic joint infections-authors' response. (Pubmed Central) -  Mar 26, 2023   
    Our study demonstrates that new lipoglycopeptides have substantially better in vitro antimicrobial activity against ocular staphylococcal isolates compared with VAN, with a similar or improved toxicity profile on HCECs. No abstract available
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    A Rare Case of Dalbavancin Induced Anaphylaxis (Walter E. Washington Convention Center, Area G, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_6104;    
    Introduction: ?Dalbavancin is a newer long-acting semisynthetic lipoglycopeptide antibiotic derived from teicoplanin, an analog of vancomycin...Subsequently, patient was initiated on empiric coverage with vancomycin and cefepime antecedent to surgical intervention...The patient received intramuscular 0.5mg of 1:1000 epinephrine with a short course of intravenous methylprednisone which led to the rapid resolution of her symptoms...Based on the available literature, excluding our patient, only 2 cases of Dalbavancin-induced anaphylaxis are reported till date. We suggest caution must be exercised while administering dalbavancin and prompt evaluation and management of anaphylaxis is mandatory to decrease morbidity and mortality associated with it.
  • ||||||||||  vancomycin / Generic mfg., Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin. (Pubmed Central) -  Mar 20, 2023   
    Dalbavancin, the first long-acting molecule with strong activity against methicillin-resistant and also many vancomycin-resistant pathogens, represented a game changer for adult ABSSSI. In pediatric settings the available literature is still limited but a growing body of evidence supports dalbavancin use in children with ABSSSI, demonstrating this drug to be safe and highly efficacious.
  • ||||||||||  vancomycin / Generic mfg., Zeven (dalbavancin) / RaQualia, AbbVie
    Clinical, Review, Journal:  The current and future off-label uses of dalbavancin: a narrative review. (Pubmed Central) -  Feb 27, 2023   
    Further randomized clinical trials are needed to assess the optimal dosing schedule depending on the site of infection. Implementing therapeutic drug monitoring for dalbavancin may represent the future step to achieving optimal pharmacokinetic/pharmacodynamic target attainment.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis. (Pubmed Central) -  Feb 23, 2023   
    The method was successfully applied for measuring DBV concentrations (range = 2.0-77.0 mg/L) in a cohort of patients receiving long-term DBV treatment of subacute and/or chronic infections. Infective endocarditis is a relatively uncommon infection that requires a high index of suspicion and its diagnosis can sometimes be challenging.Endovascular infections require long-term parenteral treatment, so outpatient parenteral antibiotic therapy (OPAT) is an option for stable patients in order to avoid prolonged hospital stays.Dalbavancin is a novel antibiotic with high activity against Gram-positive pathogens and can be administered weekly.There is growing experience in the ambulatory treatment of Gram-positive cocci endovascular infections.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Journal:  Dalbavancin Boosts the Ability of Neutrophils to Fight Methicillin-Resistant Staphylococcus aureus. (Pubmed Central) -  Feb 12, 2023   
    In conclusion, we demonstrated a cooperative effect between the antimicrobial properties of PMNs and DBV, thus owing to their immunomodulatory activity. In the choice of the treatment management of serious S. aureus infections, DBV should be considered as an outstanding option since it reinforces PMNs pathogen clearance capability by exerting its effect directly, not only on MRSA but also on neutrophils.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Review, Journal, Gram positive:  Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: A review. (Pubmed Central) -  Feb 9, 2023   
    Summary: Dalbavancin has been mainly used for skin and soft tissue infection, in particular, due to more resistant Gram-positive organisms such as methicillin-resistant Staphylococcus aureus. We review the currently available literature regarding the use of Dalbavancin in infective endocarditis.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    EN-DALBACEN (A / 06) -  Feb 4, 2023 - Abstract #ECCMID2023ECCMID_2899;